Skip to content

XOMA Corporation XOMA Milestone Assets Noncurrent

Milestone Assets Noncurrent at other companies

Theravance Biopharma logo
Theravance BiopharmaTBPH
$50M0.0%
Veradermics
 logo
Veradermics MANE
$287K
Arthur J. Gallagher logo
Arthur J. GallagherAJG
$1M
VenHub Global, Inc.
 logo
VenHub Global, Inc. VHUB
$2.28M
Schering-Plough logo
Schering-PloughSGP
$492K+8.6%
Jaguar Uranium
 logo
Jaguar Uranium JAGU
$8.19M

Other financials

Income statement

See full
Revenue$12.3M-22.6%
Operating income-$480.0K-108%
Net income$4.5M+88.6%
EPS (diluted)$0.17+183%

Balance sheet

See full
Cash & equivalents$85.6M-5.2%
Total debt$124.7M+9.0%
Total equity$92.9M+9.7%
Total assets$271.9M+27.8%

Cash flow

See full
Operating cash flow$6.1M+178%
CapEx$3.0K-29.4%
Free cash flow-$2.9M+36.0%

Valuation

See full
Market cap$746.04M+159%
Enterprise value$785.17M+152%
P/E22.1×
P/S15.4×+8.7×

Profitability

See full
Operating margin10.2%+5.5pp
Net margin69.6%+64.0pp
FCF margin-320%-118pp

Returns & leverage

See full
Return on equity38.1%+35.2pp
Debt / equity1.3×0.0×
Current ratio3.6×-2.0×

Where this comes from

Reported directly by XOMA Corporation in its filing.

Tagged under the XBRL concept xoma:MilestoneAssetsNoncurrent.

The official record: XOMA Corporation’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about XOMA Corporation's milestone assets noncurrent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is XOMA Corporation's milestone assets noncurrent?
XOMA Corporation (XOMA) reported milestone assets noncurrent of $3.7M in Q1 2026.
How has XOMA Corporation's milestone assets noncurrent changed year-over-year?
XOMA Corporation's milestone assets noncurrent increased by 12.0% year-over-year, from $3.31M to $3.7M.
What does milestone assets noncurrent mean?
This represents the capitalized value of future milestone payments expected from therapeutic development programs. These assets reflect the potential for additional cash inflows triggered by clinical or regulatory achievements by the underlying biotech partners. It is a key indicator of the company's exposure to the successful development of licensed drug candidates.